# Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

> **NCT03219723** · — · COMPLETED · sponsor: **Takeda** · enrollment: 560 (actual)

## Conditions studied

- Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Amoxicillin hydrate
- **DRUG:** Clarithromycin
- **DRUG:** Metronidazole

## Key facts

- **NCT ID:** NCT03219723
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-01
- **Primary completion:** 2017-04-30
- **Final completion:** 2017-04-30
- **Target enrollment:** 560 (ACTUAL)
- **Last updated:** 2019-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219723, "Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03219723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*